BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7102503)

  • 1. Excessive serum lidocaine levels during maintenance infusions: mechanisms and prevention.
    Davison R; Parker M; Atkinson AJ
    Am Heart J; 1982 Aug; 104(2 Pt 1):203-8. PubMed ID: 7102503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous infusion of lidocaine in patients with cardiac arrhythmias. Unpredictability of plasma concentrations.
    Sawyer DR; Ludden TM; Crawford MH
    Arch Intern Med; 1981 Jan; 141(1):43-5. PubMed ID: 7447583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-dependent lidocaine disposition in patients with acute myocardial infarction.
    Cusson J; Nattel S; Matthews C; Talajic M; Lawand S
    Clin Pharmacol Ther; 1985 Apr; 37(4):381-6. PubMed ID: 3978999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic serum lidocaine and metabolite concentrations in patients undergoing electrophysiologic study after discontinuation of intravenous lidocaine infusion.
    Estes NA; Manolis AS; Greenblatt DJ; Garan H; Ruskin JN
    Am Heart J; 1989 May; 117(5):1060-4. PubMed ID: 2711965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum concentrations of lidocaine and its metabolites after prolonged infusion in healthy horses.
    Dickey EJ; McKenzie HC; Brown KA; de Solis CN
    Equine Vet J; 2008 Jun; 40(4):348-52. PubMed ID: 18267881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Slower lidocaine elimination and dose adjustment in patients with heart failure].
    Follath F; Ritz R; Vozeh S; Wenk M
    Schweiz Med Wochenschr; 1982 May; 112(22):789-91. PubMed ID: 6808662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 4% topical lidocaine applied to the face on the serum levels of lidocaine and its metabolite, monoethylglycinexylidide.
    Oni G; Brown S; Burrus C; Grant L; Watkins J; Kenkel M; Barton F; Kenkel J
    Aesthet Surg J; 2010; 30(6):853-8. PubMed ID: 21131461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of congestive heart failure on blood vessels of lidocaine and its active monodeethylated metabolite.
    Halkin H; Meffin P; Melmon KL; Rowland M
    Clin Pharmacol Ther; 1975 Jun; 17(6):669-76. PubMed ID: 1139858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels, protein binding, and elimination data of lidocaine and active metabolites in cardiac patients of various ages.
    Drayer DE; Lorenzo B; Werns S; Reidenberg MM
    Clin Pharmacol Ther; 1983 Jul; 34(1):14-22. PubMed ID: 6861434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use and toxicity of intravenous lidocaine. A report from the Boston Collaborative Drug Surveillance Program.
    Pfeifer HJ; Greenblatt DJ; Koch-Weser J
    Am Heart J; 1976 Aug; 92(2):168-73. PubMed ID: 941829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic principles of lidocaine dosing in relation to disease state.
    Waller ES
    J Clin Pharmacol; 1981 Apr; 21(4):181-94. PubMed ID: 7240439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood levels of lidocaine after various infusion rates in patients with acute myocardial infarction.
    Rydén L; Waldenström A; Winsnes Y; Ortengren B
    Am Heart J; 1975 Apr; 89(4):470-3. PubMed ID: 1114978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple method for maintaining serum lidocaine levels in the therapeutic range.
    Wong BY; Hurwitz A
    Arch Intern Med; 1985 Sep; 145(9):1588-91. PubMed ID: 4026487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lidocaine infusions: effect of duration and method of discontinuation on recurrence of arrhythmias and pharmacokinetic variables.
    Fredrick DS; Boersma RB
    Am J Hosp Pharm; 1979 Jun; 36(6):778-81. PubMed ID: 463893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic approach to the clinical use of lidocaine intravenously.
    Greenblatt DJ; Bolognini V; Koch-Weser J; Harmatz JS
    JAMA; 1976 Jul; 236(3):273-7. PubMed ID: 947029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma concentrations of monoethylglycinexylidide during and after breast augmentation.
    Rygnestad T; Samdal F
    Plast Reconstr Surg; 2000 Sep; 106(3):728-31. PubMed ID: 10987485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional myocardial lidocaine concentration following continuous intravenous infusion early and later after myocardial infarction.
    Zito RA; Caride VJ; Holford T; Zaret BL
    Am J Cardiol; 1982 Sep; 50(3):497-502. PubMed ID: 7113933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma levels of lidocaine after intramuscular injection and subsequent infusion in patients with acute myocardial infarction.
    Oltmanns D; Lübben C; Pentz R; Siegers CP
    Int J Clin Pharmacol Ther Toxicol; 1982 Dec; 20(12):582-4. PubMed ID: 7152740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lidocaine kinetics predicted by indocyanine green clearance.
    Zito RA; Reid PR
    N Engl J Med; 1978 May; 298(21):1160-3. PubMed ID: 651945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Logical approach to lignocaine therapy.
    Aps C; Bell JA; Jenkins BS; Poole-Wilson PA; Reynolds F
    Br Med J; 1976 Jan; 1(6000):13-5. PubMed ID: 1247716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.